濮阳东方医院妇科咨询挂号濮阳东方医院妇科做人流收费合理,濮阳东方医院妇科做人流技术,濮阳东方医院男科治阳痿价格收费低,濮阳东方医院妇科收费高吗,濮阳东方医院治疗早泄,濮阳东方看男科病专业吗,濮阳东方看妇科口碑非常好

BEIJING, Feb. 23 (Xinhua) -- A senior official of the ruling Forces pour la Defense de la Democratie (FDD) of Burundi said Tuesday the FDD hopes to strengthen cooperation with the Communist Party of China (CPC) and to further enhance the "brotherly friendship" with the CPC.Mohamed Rukara, vice president of the Council of Elders, the top decision-making body of the FDD, said in an interview with Xinhua that there are a lot of ruling experiences of CPC that the FDD can learn from.He said the CPC has gained great achievements in China's reform and opening up, realizing sustainable development, developing science and technology and striking corruption.He said Burundi has set "sustainable development" as the slogan for the 2010-2015 period, and he believed that his country can learn from China's successful experiences of reform and opening up and realize the goal of shaking off poverty by 2020-2025.Rukara, who is also a ombudsman, said corruption has been a big challenge facing his country, and he believed the FDD can learn from the CPC in this regard, as the latter has been combating corruption very hard and effectively.Appreciating China's aid and contribution to the development of Burundi, Rukara said the two parties and the two countries have had very good relations based on mutual respect.He welcomed more Chinese enterprises to invest in Burundi to support its development, and "the door will always be open to our brother."At the invitation of the CPC, Rukara is heading an FDD delegation for a visit to China starting from Saturday.

WASHINGTON, April 25 (Xinhua) -- Study by scientists at the Rockefeller University shows that anti-inflammatory drugs reduce the effectiveness of the most widely used class of antidepressant medications, the selective serotonin reuptake inhibitors (SSRIs), taken for depression and obsessive-compulsive disorder and anxiety disorders.This discovery, published online Monday in the Proceedings of the National Academy of Sciences, may explain why so many depressed patients taking SSRIs do not respond to antidepressant treatment and suggests that this lack of effectiveness may be preventable.The study may be especially significant in the case of Alzheimer's disease. Such patients commonly suffer from depression and unless this can be treated successfully, the course of the illness is likely to be more severe. Depression in the elderly is also a risk factor for developing Alzheimer's Disease and researchers have suggested that treating depression in the elderly might reduce the risk of developing the disease.In the recent study, investigators treated mice with antidepressants in the presence or absence of anti-inflammatory drugs. They then examined how the mice behaved in tasks that are sensitive to antidepressant treatment. They found that the mice's behavioral responses to antidepressants were inhibited by anti- inflammatory/analgesic treatments.They then confirmed these effects in a human population. Depressed individuals who reported anti-inflammatory drug use were much less likely to have their symptoms relieved by an antidepressant than depressed patients who reported no anti- inflammatory drug use. The effect was rather dramatic since, in the absence of any anti-inflammatory or analgesic use, 54 percent of patients responded to the antidepressant, whereas success rates dropped to approximately 40 percent for those who reported using anti-inflammatory agents."Many elderly individuals suffering from depression also have arthritic or related diseases and as a consequence are taking both antidepressant and anti-inflammatory medications. Our results suggest that physicians should carefully balance the advantages and disadvantages of continuing anti-inflammatory therapy in patients being treated with antidepressant medications," leader author Paul Greengard said.

SAN FRANCISCO, May 6 (Xinhua)-- Latest research released Friday shows that Google Android has become the No.1 smartphone platform in the United States in the first quarter as more smartphone manufacturers have adopted the operating system.During the three months ending in March, Google Android grew 6. 0 percentage points to 34.7 percent market share, among the 72.5 million U.S. smartphone users, reported comScore, an Internet marketing research company.The number of smartphone users increased by 15 percent on a quarter-on-quarter basis, said the research.Research in Motion, developer of Blackberry smartphones, ranked second with 27.1 percent, a slide of 4.5 percentage points on a quarter-on-quarter basis. Apple grew 0.5 points to 25.5 percent share, followed by Microsoft (7.5 percent) and Palm (2.8 percent).According to the research, 234 million Americans age 13 and older used mobile devices in the first quarter. Samsung ranked as the top handset maker with 24.5 percent of U.S. mobile subscribers, and LG ranked second with 20.9 percent share, followed by Motorola (15.8 percent) and RIM (8.4 percent). Apple continued to gain share following the launch of the Verizon iPhone, growing by 1.1 percentage points to 7.9 percent of subscribers.On mobile content use, 68.6 percent of U.S. mobile subscribers used text messaging on their mobile device in March. Browsers were used by 38.6 percent of subscribers (up 2.2 percentage points), while downloaded applications were used by 37.3 percent (up 2.9 percentage points).Accessing of social networking sites or blogs increased 2.6 percentage points, representing 27.3 percent of mobile subscribers. Playing games comprised 25.7 percent of the mobile audience, while listening to music represented 17.9 percent, said the report.

HARBIN, March 2 (Xinhua) -- A therapeutic apparatus to treat Parkinson's disease has been developed in northeast China's Heilongjiang Province, according to the provincial science and technology department. It is a worldwide breakthrough in treating the disease with transcranial magnetic stimulation, concluded an expert panel with the Heilongjiang Provincial Department of Science and Technology.The team said it came to the conclusion after evaluating technical documents and clinical test results Monday.This is the first time that transcranial magnetic stimulation has been adopted to treat Parkinson's disease, said Sun Zuodong, chairman of Aobo Medicine Apparatus Co., Ltd. (AMA), the developer based in the provincial capital Harbin.Transcranial magnetic stimulation is a noninvasive method which causes depolarization in the brains' neurons so as to restore the functions of brain nerves.The apparatus consists of three parts, namely brain wave stimulator, field effect cap and multiplier, said Sun.Clinical tests over more than 100 patients showed that the apparatus had a 70 percent success rate in reducing the disease's symptoms, according to Wang Aili, planning manager of AMA.The new equipment will help generation of dopamine, the reduction of which within the brain caused the disease, said Wang Weixiang, a consulting doctor with the Heilongjiang Provincial Rehabilitation Hospital.Parkinson's disease is a disorder of the neural system, which leads to limb tremors and difficulty in walking and other movements.China has 2 million patients suffering from Parkinson's disease, mostly people over the age of 50, and the number is increasing by 100,000 annually, said Dr. Wang.